{"id":"NCT00395993","sponsor":"American Regent, Inc.","briefTitle":"Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding","officialTitle":"Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2006-04","completion":"2006-06","firstPosted":"2006-11-06","resultsPosted":"2013-11-18","lastUpdate":"2018-02-20"},"enrollment":456,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"type":"DRUG","name":"Ferrous Sulfate tablets","otherNames":["Oral Iron Tablets"]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Ferrous Sulfate tablets","type":"ACTIVE_COMPARATOR"}],"summary":"This study compares of the safety and efficacy of intravenous iron vs oral iron in the treatment of anemia secondary to heavy uterine bleeding","primaryOutcome":{"measure":"Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of â‰¥ 2.0 g/dL","timeFrame":"Any time between baseline and the end of study or time to intervention","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":187,"sd":null},{"arm":"Oral Iron Tablets","deltaMin":139,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["18567277","18752459","19682342"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":230},"commonTop":["Headache","Nausea","Constipation","Blood phosphorus decreased","Diarrhea"]}}